Trial Profile
A Phase 1 Study of MM-141 in Patients with Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Dec 2016
Price :
$35
*
At a glance
- Drugs Istiratumab (Primary) ; Everolimus; Gemcitabine; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Merrimack Pharmaceuticals
- 02 Dec 2016 Results of this trial, presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
- 02 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2015 Planned primary completion date changed from 1 Aug 2014 to 1 May 2016, according to ClinicalTrials.gov record.